$KROS News

Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics CFO Keith Regnante Resigns, Effective Aug. 3; VP Finance Annita Tanini Named Interim Principal Financial Officer

Keros Therapeutics Appoints Anne Prener to its Board of Directors

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate

Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

KROS Stock: What to Know About Rinvatercept in DMD

KROS: Is the Discount Book Value a Value Trap?